Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

June 2, 2023

June 2, 2023

FromThe Top Line


June 2, 2023

FromThe Top Line

ratings:
Length:
24 minutes
Released:
Jun 2, 2023
Format:
Podcast episode

Description

In this episode of the "The Top Line," Fierce’s Anastassia Gliadkovskaya talks with Autumn Ehnow, vice president of Medicines360, a nonprofit pharma with a mission to produce and sell affordable medications. They talk about the need to democratize access to medications like emergency contraception, particularly for women. We also cover Elizabeth Holmes, the state of Alzheimer's research, plus more headlines. 
To learn more about the topics in this episode: 

Startup Curae Pharma360 partners with Direct Relief to distribute free contraceptives to safety-net clinics
CMS proposes rules to expand access to contraception under ACA
HHS warns retail pharmacies to not curb access to birth control, abortion pill prescriptions
Hunt for new non-hormonal birth control sends scientists under the sea
FDA can't solve drug shortages on its own, agency's oncology chief says
Theranos' Elizabeth Holmes reports to Texas prison to begin 11-year sentence
The Alzheimer's pipeline is as strong as ever. Now, we just need the patients
Small biotech turns CRISPR against bacteria, reducing E. coli in small early study

"The Top Line" is produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.
Released:
Jun 2, 2023
Format:
Podcast episode

Titles in the series (99)

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning.